clinical trial · NCT06822426
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
CorMedix·phase3·recruiting·n = 200
Central Line Associated Blood Stream Infections (CLABSI)(taurolidine and heparin) catheter lock solutionHeparin
brief summary
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
started
May 14, 2025
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Dec 24, 2025
official title
A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol